Brokerages Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $65.00

by · The Cerbat Gem

Shares of XOMA Royalty Corporation (NASDAQ:XOMA – Get Free Report) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $60.60.

Several equities research analysts have recently commented on XOMA shares. UBS Group set a $76.00 price target on shares of XOMA Royalty in a research report on Tuesday, December 9th. Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a research report on Friday, December 12th. HC Wainwright reduced their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a report on Friday, December 12th. Finally, Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th.

Read Our Latest Report on XOMA

XOMA Royalty Trading Down 2.2%

XOMA stock opened at $25.26 on Thursday. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $39.92. The company has a market cap of $312.72 million, a P/E ratio of 34.14 and a beta of 0.94. The business has a fifty day moving average of $32.64 and a 200-day moving average of $31.03.

XOMA Royalty (NASDAQ:XOMA – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The firm had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. As a group, equities research analysts expect that XOMA Royalty will post -1.41 EPS for the current year.

Insider Activity at XOMA Royalty

In other news, CEO Owen Hughes acquired 100,000 shares of XOMA Royalty stock in a transaction that occurred on Thursday, December 4th. The shares were acquired at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the purchase, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at $2,555,100. The trade was a 5,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Thomas M. Burns sold 4,330 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total transaction of $155,836.70. Following the completion of the sale, the chief financial officer directly owned 30,079 shares of the company’s stock, valued at $1,082,543.21. The trade was a 12.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its stake in XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the period. Tower Research Capital LLC TRC grew its position in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares during the period. JPMorgan Chase & Co. increased its stake in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in XOMA Royalty during the 2nd quarter worth approximately $116,000. Finally, BNP Paribas Financial Markets lifted its stake in XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 2,346 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors.

XOMA Royalty Company Profile

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

See Also